The Kirsten Rat Sarcoma (KRAS) market in the Asia-Pacific region is undergoing a transformative period, driven by a surge in precision oncology and molecular diagnostics. The KRAS gene is a critical biomarker in various aggressive cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. As medical infrastructure in the region evolves, the focus has...